Weitz & Luxenberg is no longer accepting Trasylol cases
Serious Risks Associated With Trasylol and Heart Surgery. Speak with our lawyers about your experience.
Get a FREE case review from our Trayslol lawyers
Trasylol, known generically as aprotinin, was used to control bleeding in hundreds of thousands of heart-bypass patients since the Food and Drug Administration approved it in 1993.
Bayer AG, marketer of the drug, was forced to pull it from the market last year, after researchers linked it to serious side effects like kidney failure, heart attacks, and strokes.
Some who have been harmed by the pharmaceutical have begun to seek out our Drug and Medical Device lawyers.
Two studies published in the February 2008 issue of the New England Journal of Medicine support earlier finding that the drug is unsafe.
The first study looked at about 10,000 patients who had bypasses at Duke University Medical Center from 1996 through 2005.
It found that 6.4 percent of patients who were given Trasylol died within 30 days of the surgery, a rate nearly 2.5 times higher than patients who got another drug or who received no treatment for bleeding.
The second study, financed by Bayer, looked at about 78,000 patients nationwide from 2003 to 2006.
Researchers found the risk of death was 64 percent higher in the Trasylol group than in those taking a comparison drug.
Complete the form below for a free legal review of your case by our Trayslol lawyers.
News & Warnings
FDA Health Advisory
FDA Approval Letter
|Frequently Asked Questions|
Trasylol News Updated News on the Harmful Health Risks Associated with Trasylol
Get Trasylol news and a free legal review of your case from a lawyer
Learn More Learn more about the FDA Trasylol alert from an experienced lawyer
Health Alert: Learn about the FDA Advisory for Trasylol from a lawyer
Research Center Serious Risks Associated With Trasylol and Heart Surgery. Lawyers Info
Research Trasylol and get lawsuit information from Trasylol lawyers